CATEGORY: WOMEN’S HEALTH
A urinary tract infection is usually treated with one of a handful of oral antibiotics, and that handful keeps shrinking as resistance spreads. Gepotidacin is the first genuinely new type to reach late-stage trials in a generation. Tested against the standard antibiotic nitrofurantoin in two randomized trials of more than 3,000 women and adolescent girls, it cured infections at least as reliably. In one of the two it did significantly better, curing 58.5% against 43.6%.1
Two Locks Changed at Once
The drug jams two of the enzymes bacteria use to copy their own DNA, gripping them at a binding site no current antibiotic uses. Because it leans on both enzymes in a balanced way, a single mutation is unlikely to defeat it. Change the locks on two doors at once, and one copied key no longer gets a burglar in. The study authors note that gepotidacin stays active against bacteria that have already developed resistance to existing drugs.
A Strict Definition of Cured
The EAGLE-2 and EAGLE-3 trials ran at 219 centers worldwide, sorting non-pregnant women and girls aged 12 and older who had symptoms and urine evidence of infection into a five-day course of either gepotidacin or nitrofurantoin, a long-standing first-choice UTI antibiotic. Sorting was random, and concealed from both sides. About ten days after starting treatment, each participant was scored against an unusually strict double bar. Success meant symptoms completely resolved and laboratory tests confirming the bacteria were cleared, with no other antibiotics needed. Partial improvement counted as failure, which is why the cure numbers look lower than everyday experience suggests. Both trials were stopped early for efficacy at a planned interim checkpoint, so the primary results come from the roughly 600 patients per trial evaluable at that point.
Level in One Trial, Ahead in the Other
The trials were designed to ask a modest question: is the new drug at least no worse? One of them came back with a stronger answer. In EAGLE-2, 162 of 320 women on gepotidacin (50.6%) met the strict cure standard, against 135 of 287 (47.0%) on nitrofurantoin, statistically no worse. In EAGLE-3 gepotidacin was superior, 162 of 277 cured (58.5%) against 115 of 264 (43.6%), an adjusted difference of 14.6 percentage points (95% confidence interval, 6.4 to 22.8). Matching the standard was the goal. Beating it was the outcome the design allowed for but did not require.
Loose Stools, Not Serious Harms
The tradeoff showed up in the gut. Diarrhea was the most common side effect of gepotidacin, affecting 14% of patients in one trial and 18% in the other, against nausea in about 4% on nitrofurantoin. Cases were mostly mild or moderate, and no life-threatening or fatal events occurred in either trial. The research was funded by GSK, which makes gepotidacin, together with BARDA, the US biomedical preparedness agency that co-funds antibiotic development because resistant infections are a public health threat.
Key Takeaways
- Gepotidacin, the first genuinely new type of oral UTI antibiotic in a generation, matched nitrofurantoin in both trials and outperformed it in one, curing 58.5% against 43.6%.
- Counting as cured required both complete symptom resolution and lab-confirmed clearance of the bacteria, a stricter bar than the everyday sense of the word.
- Diarrhea was the most common side effect, mostly mild to moderate, and no serious drug-related harms occurred.
- A new antibiotic class matters beyond any single prescription, because it stays active against bacteria already resistant to current UTI drugs.
References
- Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403(10428):741–755. link